Kravchenko A V
Ter Arkh. 2010;82(11):27-32.
The paper gives the results of the largest international studies demonstrating the efficacy and safety of Raltegravir as part of antiretroviral treatment (ARVT) regimens in both patients starting therapy (STARTMRK study) and those pretreated with antiretroviral drugs (BENCHMRK study). The advantage of Raltegravir over Efavirens is the lower incidence of adverse central nervous system reactions. Based on the results of published investigations, specialists from the USA and European Union have incorporated the first HIV integrase inhibitor Raltegravir into a first-line ARTV regimen. Raltegravir is the drug of choice and should be used in special categories of patients, such as those with chronic hepatitis C or fat metabolic disturbances.
该论文给出了最大规模国际研究的结果，这些研究证明了雷特格韦作为抗逆转录病毒治疗（ARVT）方案的一部分，在初治患者（STARTMRK研究）和接受过抗逆转录病毒药物预处理的患者（BENCHMRK研究）中的疗效和安全性。雷特格韦相对于依非韦伦的优势在于中枢神经系统不良反应的发生率较低。基于已发表的研究结果，美国和欧盟的专家已将首个HIV整合酶抑制剂雷特格韦纳入一线抗逆转录病毒治疗方案。雷特格韦是首选药物，应用于特殊类型的患者，如患有慢性丙型肝炎或脂肪代谢紊乱的患者。
